Chiusura precedente | 145,36 |
Aperto | 143,40 |
Denaro | 139,60 x 1200 |
Lettera | 140,00 x 1300 |
Min-Max giorno | 140,95 - 149,75 |
Intervallo di 52 settimane | 115,61 - 497,49 |
Volume | |
Media Volume | 6.016.019 |
Capitalizzazione | 56,557B |
Beta (5 anni mensile) | 1,69 |
Rapporto PE (ttm) | 4,24 |
EPS (ttm) | 33,54 |
Prossima data utili | 03 ago 2022 - 08 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 219,33 |
- Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti Bioscien
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Moderna, Inc. (NASDAQ: MRNA), PharmaDrug (OTC: LMLLF) (CSE: PHRX) Tilray, Inc. (NASDAQ:TLRY) and Vinco Ventures (NASDAQ: BBIG). Today’s emerging technologies and lifestyle megatrends are unleashing trillion dollar market opportunities for disruptive innovation in how we live, work and play. Wall Street Reporter